-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Spring is blooming, and all things are revived
.
The 2022 ASCO GU has quietly come to an end
.
This article summarizes the major research progress in the three major tumor types at this year's ASCO GU conference.
Let's review it together! Urothelial cancer 01 Expert interpretation of the treatment of upper urothelial carcinoma (UTUC) in general lack of high-level evidence-based medical evidence, and in most cases need to refer to the treatment of bladder urothelial carcinoma (UBC) from the lower urinary tract to proceed
.
Therefore, the level of diagnosis and treatment of UTUC needs to be improved urgently
.
Every year, ASCO GU has a certain number of UTUC studies, which represent the international frontier progress in this field
.
Recommended reading: 2022 ASCO GU | Prof.
Xinan Sheng: Inventory of the research progress of upper urinary tract urothelial carcinoma New breakthroughs in recent years have made HER2 a hot spot in urothelial carcinoma research again.
This ASCO GU conference has a number of HER2-related studies Progress, this article organizes the relationship between HER2 changes and the clinical course and prognosis of urothelial carcinoma, the impact on conventional chemotherapy and immunotherapy, and the new progress of anti-HER2 therapy
.
Recommended reading: 2022 ASCO GU | Prof.
Xinan Sheng: Advances in HER2-related research in urothelial cancer 02 Bladder-sparing radical cystectomy (RC) is considered the "gold standard" for muscle-invasive bladder cancer (MIBC)
.
The treatment modality for many tumor types has shifted from surgery to organ-sparing, and the combination of limited resection and chemoradiotherapy is often referred to as triple therapy (TMT)
.
Triple therapy for MIBC refers to concurrent chemoradiotherapy followed by maximal transurethral resection of bladder tumor (TURBT)
.
Whether TURBT can replace RC is still up in the air
.
Recommended reading: 2022 ASCO GU | Large retrospective analysis: triple therapy can replace RC in MIBC The results of the phase III QUILT 3.
032 study presented at this year's ASCO GU conference lead to bladder preservation for high-grade non-muscle invasive bladder cancer (NMIBC) new choice
.
Recommended reading: A new weapon for high-grade non-muscle invasive bladder cancer: N-803+ BCG bladder retention rate of 92% | 2022 ASCO GU03 Neoadjuvant therapy Enfortumab vedotin (EV) in the urethral tract that is not suitable for cisplatin-containing therapy Efficacy and safety in patients with cutaneous cancer have been recognized and FDA approved for previously treated patients with advanced urothelial cancer, but the efficacy of EV in neoadjuvant therapy remains unclear
.
Recommended reading: 2022 ASCO GU | EV enters the "front line": neoadjuvant therapy pCR rate reaches 36.
4%! UTUC is rare but has a poor prognosis
.
At this year's ASCO GU conference, researchers announced the efficacy of neoadjuvant chemotherapy for UTUC patients
.
Recommended reading: 2022 ASCO GU | GC is expected to become the standard neoadjuvant therapy for UTUC patients What is the efficacy of maintenance therapy after biomarker-selected chemotherapy? Recommended reading: 2022 ASCO GU | PARP inhibitor for maintenance treatment of urothelial carcinoma, what is the efficacy? 05First-line treatment Platinum-containing chemotherapy is the main first-line treatment for advanced urothelial carcinoma, and patients who are not suitable for platinum-based chemotherapy have worse prognosis and limited treatment options
.
At this year's ASCO GU conference, the plenary session, oral presentations and quick abstracts, there were three studies on first-line treatment options for platinum-inappropriate advanced urothelial carcinoma announced
.
The results of the study are not satisfactory, but the results also provide new information and new ideas for further exploration of new options for advanced urothelial cancer
.
Recommended reading: 2022 ASCO GU | Long Road: An Inventory of Research Progress in First-Line Treatment of Advanced Urothelial Carcinoma 06 Second-Line Treatment At this year's ASCO GU conference, there were three studies involving the research plan after the progress of platinum-based treatment for metastatic urothelial carcinoma, The results suggest that immunotherapy + antibody-drug conjugates (ADC), immune single-drug sequential dual-immunotherapy combination therapy may become a new choice for second-line treatment of patients with metastatic urothelial carcinoma! Recommended reading: 2022 ASCO GU | Individualization + powerful combination, leading a new era of advanced UC second-line treatment of prostate cancer The exploration of cancer biomarkers is discussed
.
Recommended reading: 2022 ASCO GU Sneak Peek | AI Powered! Exploratory study of localized prostate cancer biomarkers In localized prostate cancer, the field of neoadjuvant therapy is one of the hot topics of discussion
.
At this ASCO GU meeting, the ACDC-RP study evaluated neoadjuvant therapy for localized prostate cancer
.
Recommended reading: 2022 ASCO GU | The application of abiraterone ± cabazitaxel in neoadjuvant treatment of patients with localized prostate cancer at high risk Changing the future treatment landscape for advanced prostate cancer
.
Recommended reading: 2022 ASCO GU heavy progress | Combination therapy to advance a new era of advanced prostate cancer Inhibition of androgen receptor (AR) function is one of the 4 main mechanisms of androgen deprivation therapy (ADT), and it is also the main mechanism of advanced prostate cancer.
treatment strategy
.
Drug research and development targeting AR has been a hot topic for a long time, and it has also continued to promote a variety of drugs into clinical applications
.
At this ASCO GU meeting, the research results of two novel AR inhibitors, ARV-110 and ODM-208, were announced
.
Recommended reading: 2022 ASCO GU | Prostate Cancer: Two Novel AR Inhibitors Show Their Edge resection, and the efficacy of neoadjuvant therapy and adjuvant therapy is still unclear
.
In recent years, with the popularity of immunotherapy, the strategy of immunotherapy has also been actively explored in renal cancer
.
Recommended reading: 2022 ASCO GU | The exploration of immunotherapy in neoadjuvant and adjuvant therapy for renal cell carcinoma type renal cell carcinoma (ccRCC)
.
In the first-line treatment of advanced ccRCC, immunotherapy is one of the hot areas in recent years
.
At this ASCO GU meeting, two studies evaluated the use of nivolumab (nivo) in treatment-naïve advanced ccRCC
.
Recommended reading: 2022 ASCO GU | Exploring the first-line treatment of nivolumab in advanced clear cell renal cell carcinoma will be more handy
.
At this ASCO GU meeting, two studies assessed genomic alterations in patients with renal cell carcinoma
.
Suggested Reading: 2022 ASCO GU | An Overview of Genomics Research in Renal Cell Carcinoma
.
The 2022 ASCO GU has quietly come to an end
.
This article summarizes the major research progress in the three major tumor types at this year's ASCO GU conference.
Let's review it together! Urothelial cancer 01 Expert interpretation of the treatment of upper urothelial carcinoma (UTUC) in general lack of high-level evidence-based medical evidence, and in most cases need to refer to the treatment of bladder urothelial carcinoma (UBC) from the lower urinary tract to proceed
.
Therefore, the level of diagnosis and treatment of UTUC needs to be improved urgently
.
Every year, ASCO GU has a certain number of UTUC studies, which represent the international frontier progress in this field
.
Recommended reading: 2022 ASCO GU | Prof.
Xinan Sheng: Inventory of the research progress of upper urinary tract urothelial carcinoma New breakthroughs in recent years have made HER2 a hot spot in urothelial carcinoma research again.
This ASCO GU conference has a number of HER2-related studies Progress, this article organizes the relationship between HER2 changes and the clinical course and prognosis of urothelial carcinoma, the impact on conventional chemotherapy and immunotherapy, and the new progress of anti-HER2 therapy
.
Recommended reading: 2022 ASCO GU | Prof.
Xinan Sheng: Advances in HER2-related research in urothelial cancer 02 Bladder-sparing radical cystectomy (RC) is considered the "gold standard" for muscle-invasive bladder cancer (MIBC)
.
The treatment modality for many tumor types has shifted from surgery to organ-sparing, and the combination of limited resection and chemoradiotherapy is often referred to as triple therapy (TMT)
.
Triple therapy for MIBC refers to concurrent chemoradiotherapy followed by maximal transurethral resection of bladder tumor (TURBT)
.
Whether TURBT can replace RC is still up in the air
.
Recommended reading: 2022 ASCO GU | Large retrospective analysis: triple therapy can replace RC in MIBC The results of the phase III QUILT 3.
032 study presented at this year's ASCO GU conference lead to bladder preservation for high-grade non-muscle invasive bladder cancer (NMIBC) new choice
.
Recommended reading: A new weapon for high-grade non-muscle invasive bladder cancer: N-803+ BCG bladder retention rate of 92% | 2022 ASCO GU03 Neoadjuvant therapy Enfortumab vedotin (EV) in the urethral tract that is not suitable for cisplatin-containing therapy Efficacy and safety in patients with cutaneous cancer have been recognized and FDA approved for previously treated patients with advanced urothelial cancer, but the efficacy of EV in neoadjuvant therapy remains unclear
.
Recommended reading: 2022 ASCO GU | EV enters the "front line": neoadjuvant therapy pCR rate reaches 36.
4%! UTUC is rare but has a poor prognosis
.
At this year's ASCO GU conference, researchers announced the efficacy of neoadjuvant chemotherapy for UTUC patients
.
Recommended reading: 2022 ASCO GU | GC is expected to become the standard neoadjuvant therapy for UTUC patients What is the efficacy of maintenance therapy after biomarker-selected chemotherapy? Recommended reading: 2022 ASCO GU | PARP inhibitor for maintenance treatment of urothelial carcinoma, what is the efficacy? 05First-line treatment Platinum-containing chemotherapy is the main first-line treatment for advanced urothelial carcinoma, and patients who are not suitable for platinum-based chemotherapy have worse prognosis and limited treatment options
.
At this year's ASCO GU conference, the plenary session, oral presentations and quick abstracts, there were three studies on first-line treatment options for platinum-inappropriate advanced urothelial carcinoma announced
.
The results of the study are not satisfactory, but the results also provide new information and new ideas for further exploration of new options for advanced urothelial cancer
.
Recommended reading: 2022 ASCO GU | Long Road: An Inventory of Research Progress in First-Line Treatment of Advanced Urothelial Carcinoma 06 Second-Line Treatment At this year's ASCO GU conference, there were three studies involving the research plan after the progress of platinum-based treatment for metastatic urothelial carcinoma, The results suggest that immunotherapy + antibody-drug conjugates (ADC), immune single-drug sequential dual-immunotherapy combination therapy may become a new choice for second-line treatment of patients with metastatic urothelial carcinoma! Recommended reading: 2022 ASCO GU | Individualization + powerful combination, leading a new era of advanced UC second-line treatment of prostate cancer The exploration of cancer biomarkers is discussed
.
Recommended reading: 2022 ASCO GU Sneak Peek | AI Powered! Exploratory study of localized prostate cancer biomarkers In localized prostate cancer, the field of neoadjuvant therapy is one of the hot topics of discussion
.
At this ASCO GU meeting, the ACDC-RP study evaluated neoadjuvant therapy for localized prostate cancer
.
Recommended reading: 2022 ASCO GU | The application of abiraterone ± cabazitaxel in neoadjuvant treatment of patients with localized prostate cancer at high risk Changing the future treatment landscape for advanced prostate cancer
.
Recommended reading: 2022 ASCO GU heavy progress | Combination therapy to advance a new era of advanced prostate cancer Inhibition of androgen receptor (AR) function is one of the 4 main mechanisms of androgen deprivation therapy (ADT), and it is also the main mechanism of advanced prostate cancer.
treatment strategy
.
Drug research and development targeting AR has been a hot topic for a long time, and it has also continued to promote a variety of drugs into clinical applications
.
At this ASCO GU meeting, the research results of two novel AR inhibitors, ARV-110 and ODM-208, were announced
.
Recommended reading: 2022 ASCO GU | Prostate Cancer: Two Novel AR Inhibitors Show Their Edge resection, and the efficacy of neoadjuvant therapy and adjuvant therapy is still unclear
.
In recent years, with the popularity of immunotherapy, the strategy of immunotherapy has also been actively explored in renal cancer
.
Recommended reading: 2022 ASCO GU | The exploration of immunotherapy in neoadjuvant and adjuvant therapy for renal cell carcinoma type renal cell carcinoma (ccRCC)
.
In the first-line treatment of advanced ccRCC, immunotherapy is one of the hot areas in recent years
.
At this ASCO GU meeting, two studies evaluated the use of nivolumab (nivo) in treatment-naïve advanced ccRCC
.
Recommended reading: 2022 ASCO GU | Exploring the first-line treatment of nivolumab in advanced clear cell renal cell carcinoma will be more handy
.
At this ASCO GU meeting, two studies assessed genomic alterations in patients with renal cell carcinoma
.
Suggested Reading: 2022 ASCO GU | An Overview of Genomics Research in Renal Cell Carcinoma
